Monte Rosa Therapeutics, Inc. (GLUE)
| Market Cap | 1.47B +480.1% |
| Revenue (ttm) | 42.95M -73.1% |
| Net Income | -130.01M |
| EPS | -1.50 |
| Shares Out | 84.48M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 729,623 |
| Open | 17.48 |
| Previous Close | 17.59 |
| Day's Range | 17.09 - 18.07 |
| 52-Week Range | 4.12 - 25.77 |
| Beta | 1.60 |
| Analysts | Strong Buy |
| Price Target | 32.33 (+86.23%) |
| Earnings Date | May 7, 2026 |
About GLUE
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1α, IL-1β and IL... [Read more]
Financial Performance
In 2025, Monte Rosa Therapeutics's revenue was $123.67 million, an increase of 63.54% compared to the previous year's $75.62 million. Losses were -$38.63 million, -46.87% less than in 2024.
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for GLUE stock is "Strong Buy." The 12-month stock price target is $32.33, which is an increase of 86.23% from the latest price.
News
Monte Rosa Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing multiple molecular glue degrader programs in I&I and oncology, with key phase II studies upcoming in NEK7 (inflammation), VAV1 (autoimmune, partnered with Novartis), and GSPT1 (prostate cancer). Strong early clinical data and strategic interest position the pipeline for significant milestones this year.
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today ann...
Monte Rosa Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
The conference highlighted progress in molecular glue degraders for oncology and inflammation, with MRT-2359 advancing to phase II in AR mutant prostate cancer and NEK7 degrader MRT-8102 showing strong CRP reduction. Multiple new trials and INDs are planned across the pipeline.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
BOSTON, May 20, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today anno...
Monte Rosa Therapeutics price target raised to $31 from $30 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $31 from $30 and keeps an Overweight rating on the shares.
Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M
“We continue to make excellent progress advancing multiple programs through the clinic, with all three of our clinical-stage programs approaching Phase 2 trial initiations,” said Markus Warmuth, Chief...
Monte Rosa Therapeutics Announces First Quarter 2026 Financial Results and Business Updates
Interim clinical data from GFORCE-1 trial of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in subjects with elevated CVD risk; readout of expanded GFORCE-1 trial in subjects with ele...
Monte Rosa Therapeutics Earnings release: Q1 2026
Monte Rosa Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Monte Rosa Therapeutics Quarterly report: Q1 2026
Monte Rosa Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
Monte Rosa Therapeutics Slides: Corporate presentation
Monte Rosa Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 6, 2026.
Monte Rosa Therapeutics Proxy statement: Proxy filing
Monte Rosa Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Monte Rosa Therapeutics Proxy statement: Proxy filing
Monte Rosa Therapeutics filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
Monte Rosa Therapeutics to present preclinical data on MRT-55811
Monte Rosa Therapeutics (GLUE) announced the company will present preclinical data highlighting the potential of its highly selective, first-in-class cyclin E1-directed MGD, MRT-55811, to treat CCNE1-...
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2026 on the Potential of its Cyclin E1 (CCNE1)-directed Molecular Glue Degrader to Treat CCNE1-amplified Solid Tumors
CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior selectiv...
Monte Rosa Therapeutics price target lowered to $30 from $34 at Guggenheim
Guggenheim lowered the firm’s price target on Monte Rosa Therapeutics (GLUE) to $30 from $34 and keeps a Buy rating on the shares. The firm, which is updating its model…
Monte Rosa Therapeutics reports Q4 collaboration revenue $2.78M
Collaboration revenue in the same quarter last year was $60.65M. Net loss for the fourth quarter of 2025 was $46.1M, compared to $13.4M for the fourth quarter of 2024. Expects…
Monte Rosa Therapeutics reports Q4 revenue $2.8M, consensus $15.51
Expects its cash and cash equivalents to be sufficient to fund planned operations and capital expenditures into 2029. “Monte Rosa is now on the cusp of Phase 2 trial initiations…
Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
Positive interim Phase 1 data of NEK7-directed MGD MRT-8102 demonstrated profound CRP reductions in elevated CVD-risk subjects; readout of expanded part 3 CRP PoC trial (now called GFORCE-1) anticipat...
Monte Rosa Therapeutics Annual report: Q4 2025
Monte Rosa Therapeutics has published its Q4 2025 annual report on March 17, 2026.
Monte Rosa Therapeutics Earnings release: Q4 2025
Monte Rosa Therapeutics released its Q4 2025 earnings on March 17, 2026, summarizing the period's financial results.
Monte Rosa Therapeutics announces clinical supply agreement with Johnson & Johnson
Monte Rosa Therapeutics (GLUE) announced the company has entered into a supply agreement with Johnson & Johnson to evaluate MRT-2359 in combination with ERLEADA for the treatment of patients with…
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Monte Rosa Therapeutics Announces Clinical Supply Agreement to Support Phase 2 Trial Evaluating MRT-2359 in Combination with Apalutamide for the Treatment
Monte Rosa Therapeutics Slides: Corporate presentation
Monte Rosa Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 16, 2026.
Monte Rosa Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Molecular glue degraders are advancing clinical programs targeting undruggable proteins, with MRT-8102 showing strong CRP reduction and safety in early studies. Key catalysts include GFORCE-1 data in H2 2024, phase II trials for MRT-6160, and a signal-confirming study for MRT-2359 in AR-mutant prostate cancer.
Monte Rosa Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing a pipeline of molecular glue degraders, with strong clinical data in NEK7 and GSPT1 programs and multiple phase II trials set for 2024. Strategic partnerships and a robust financial position support expansion into new indications and second-generation molecules.